HELP
Cybin Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · CA
$12.22
+3.82%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -19.9%
- EBIT
- -19.7%
- EPS
- +7.2%
- Free cash flow
- -58.7%
- Operating cash flow
- -60.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +89.1%
- EPS
- +53.7%
Three-year CAGR
- Revenue
- —
- EBITDA
- +1.0%
- EBIT
- +1.0%
- Net income
- -30.0%
- EPS
- +24.3%
- Free cash flow
- -29.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026